SCHEMBL4581753

SCHEMBL4581753

COc1ccc2c(ccn2-c2ccc(C(N)=O)cc2Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.50
PIM1 P11309 1/20 0.50
PIM3 Q86V86 1/20 0.50
ROCK1 Q13464 1/20 0.44
PARP1 P09874 2/20 0.43
PARP10 Q53GL7 2/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
PARP2 Q9UGN5 1/20 0.43
PARP4 Q9UKK3 1/20 0.43
KDM4E B2RXH2 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TUBB1 Q9H4B7 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
HDAC6 Q9UBN7 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4578786 0.84 ROCK2 (0.45) ROCK2PIM1PIM3TUBB1HDAC6
SCHEMBL14291380 0.81 ROCK1 (0.51) ROCK1KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL4580698 0.81 ROCK2 (0.54) ROCK2PIM1PIM3PARP1PARP2
SCHEMBL31116815 0.77 ROCK1 (0.51) ROCK1KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL4580723 0.76 ROCK1 (0.43) ROCK1KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL9702109 0.73 KDM4E (0.70) PARP1PARP10CA1CA2PARP2
SCHEMBL5427894 0.71 ROCK1 (0.51) ROCK1KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL14313067 0.69 TUBB1 (0.60) ROCK1PARP1KDM4EL3MBTL1ALDH1A1
SCHEMBL31454935 0.69 ROCK1 (0.54) ROCK1KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL28842817 0.69 ROCK1 (0.48) ROCK1KDM4EL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-05-22 US claimed
WO-2008024978-A2 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO claimed
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-05-22 US disclosed
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-05-22 US disclosed
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives SERENEX, INC. 2008-05-22 US disclosed
WO-2008024978-A2 TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES SERENEX, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119457-A1 Benzene, Pyridine, and Pyridazine Derivatives MKI67, CCNB1, RB1 ROCK2 2857/4885PIM1 1374/4885PIM3 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.